Table 7: ICERs for palivizumab prophylaxis for healthy term infants in the Canadian Arctic, comparing scenario A, in which prophylaxis is continued to end of RSV season, to scenario B, in which prophylaxis is stopped at 5 months of age

Variable	Northwest Territories	Nunavut	Nunavut without Iqaluit	Kitikmeot Region	Kivalliq Region	Qikiqtaaluk Region	Qikiqtaaluk Region without Iqaluit	Nunavik
Base case (no prophylaxis)
Total costs, $	177 256	2 871 137	2 856 561	1 496 365	1 094 603	280 169	265 593	632 139
No. of admissions for RSV infection	8	52	51	22	18	12	11	30
Scenario A
Total costs, $	4 374 645	4 937 207	4 256 984	733 714	1 491 713	2 711 781	2 031 558	1 502 765
No. of admissions for RSV infection	0.3	2.1	2	0.9	0.7	0.5	0.4	1.2
Scenario B
Total costs, $	2 690 852	3 457 312	3 039 106	705 024	1 058 004	1 694 285	1 276 078	990 964
No. of admissions for RSV infection	0.3	11.7	11.6	5.7	4.6	1.4	1.4	7
Scenario A v. base case
Incremental costs, $	4 197 389	2 066 070	1 400 423	-762 652	397 111	2 431 611	1 765 965	870 625
Incremental no. of RSV-related admissions	7.7	49.9	49	21.1	17.3	11.5	10.6	28.8
ICER (cost per RSV-related admission avoided), $	545 115	41 404	28 580	-36 145	22 954	211 444	166 600	30 230
Scenario B v. base case
Incremental costs, $	2 513 597	586 175	182 545	-791 342	-36 599	1 414 116	1 010 486	358 825
Incremental no. of RSV-related admissions	7.7	40.3	39.4	16.3	13.4	10.6	9.6	23
ICER (cost per RSV-related admission avoided), $	326 441	14 545	4633	-48 549	-2731	133 407	105 259	15 601
Scenario A v. scenario B
Incremental costs, $	1 683 793	1 479 895	1 217 878	28 690	433 709	1 017 496	755 480	511 801
Incremental no. of RSV-related admissions	0	9.6	9.6	4.8	3.9	0.9	1	5.8
ICER (cost per RSV-related admission avoided), $	-	154 156	126 862	5977	111 207	1 130 551	755 480	88 242

Note: ICER = incremental cost-effectiveness ratio, RSV = respiratory syncytial virus.